Menu
  • Join us
  • Login
 

Search for abstracts

You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.


Identification of a novel inhibitor for hepatitis B virus internalization targeting viral receptor oligomerization

  • At: PSWC2020 (2020)
  • Type: Poster
  • By: FUKANO, Kento (National Institute of Infectious Diseases, Department of Virology II, Japan)
  • Co-author(s): Kento Fukano: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Senko Tsukuda: Liver Cancer Prevention Research Unit, Center for Integrative Medical Sciences, RIKEN, Saitama, Japan;Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Mizuki Oshima: Department of Applied Biological Science, Tokyo University of Science, Chiba, Japan;Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Mio Ohki: Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
    Sam-Yong Park: Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
    Kousho Wakae: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Hideki Aizaki: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Takaji Wakita: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
    Koichi Watashi: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan;Department of Applied Biological Science, Tokyo University of Science, Chiba, Japan
    Masamichi Muramatsu: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
  • Abstract:

    Background

    Current anti-HBV agents including nucleos(t)ide analogs and interferons can reduce the viral load, but are not generally curative.  Thus, the development of anti-HBV agents with different modes of action is required to improve treatment outcomes.

    Purpose

    In this study, we aim to identify small molecules inhibiting HBV internalization as

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 23 September 2026

FIP Congresses